Use of full-dose contrast-enhanced CT for extrahepatic staging using Gallium-68-DOTATATE PET/CT in patients with neuroendocrine tumors | Zendy

Jonas Apitzsch | Zendy; Frederik A. Verburg | Zendy; Felix M. Mottaghy | Zendy; Alexander Heinzel | Zendy

Open Access

Use of full-dose contrast-enhanced CT for extrahepatic staging using Gallium-68-DOTATATE PET/CT in patients with neuroendocrine tumors

Author(s) -

Jonas Apitzsch,

Frederik A. Verburg,

Felix M. Mottaghy,

Alexander Heinzel

Publication year - 2021

Publication title -

diagnostic and interventional radiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.754

H-Index - 43

eISSN - 1305-3612

pISSN - 1305-3825

DOI - 10.5152/dir.2021.19424

Subject(s) - medicine , nuclear medicine , positron emission tomography , neuroendocrine tumors , radiology , pet ct , lymph node , lesion , lung , pathology

Studies have demonstrated that positron emission tomography/computed tomography (PET/CT) with Gallium-68 (68Ga)-labeled somatostatin analogues are effective at detecting metastatic disease in neuroendocrine tumors (NET), especially extrahepatic metastases. However, PET in combination with full-dose contrast-enhanced CT (ceCT) exposes patients to higher radiation (~25 mSv). The use of non-contrast-enhanced low-dose CT (ldCT) can reduce radiation to about 10 mSv and may avoid contrast-induced side effects. This study seeks to determine whether ceCT could be omitted from NET assessments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research